BioAegis Licenses Protein for Development

BioAegis Therapeutics has entered into an exclusive option agreement with Brigham and Women’s Hospital granting BioAegis a worldwide license for therapeutic and diagnostic use of Brigham’s technology for human and animal applications. The technology is based on the research of founding scientist Dr. Thomas Stossel, director, Translational Medicine at Brigham and Women’s Hospital, and collaborators at Massachusetts General Hospital, University of Pennsylvania, Beth Israel Deaconess Medical Center and BloodCenter of Wisconsin.

Dr. Stossel said, “Plasma gelsolin is just beginning to reveal its fundamental role in immune function and inflammation. BioAegis is committed to a broad set of translational objectives which promise to deliver high value therapeutics to patients.”

Plasma gelsolin is the fourth most prevalent protein in human blood and levels in humans and in animal models are known to be depleted in several acute and chronic diseases. In humans, depletion of pGSN correlates with severity of disease and the relative risk of adverse outcomes. Replacement of depleted pGSN has been shown to prevent adverse outcomes in animal models.